Cargando…
Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis
Lipoarabinomannan (LAM), a component of the Mycobacterium tuberculosis (MTB) cell wall, is detectable in the urine of MTB infected patients with active tuberculosis (TB). LAM-specific antibodies (Igs) have been developed by a variety of traditional and recombinant methods for potential use in a rapi...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524686/ https://www.ncbi.nlm.nih.gov/pubmed/36178936 http://dx.doi.org/10.1371/journal.pone.0274415 |
_version_ | 1784800548145332224 |
---|---|
author | Cantera, Jason L. Lillis, Lorraine M. Peck, Roger B. Moreau, Emmanuel Schouten, James A. Davis, Paul Drain, Paul K. Andama, Alfred Pinter, Abraham Kawasaki, Masanori Källenius, Gunilla Sundling, Christopher Dobos, Karen M. Flores, Danara Chatterjee, Delphi Murphy, Eileen Halas, Olivia R. Boyle, David S. |
author_facet | Cantera, Jason L. Lillis, Lorraine M. Peck, Roger B. Moreau, Emmanuel Schouten, James A. Davis, Paul Drain, Paul K. Andama, Alfred Pinter, Abraham Kawasaki, Masanori Källenius, Gunilla Sundling, Christopher Dobos, Karen M. Flores, Danara Chatterjee, Delphi Murphy, Eileen Halas, Olivia R. Boyle, David S. |
author_sort | Cantera, Jason L. |
collection | PubMed |
description | Lipoarabinomannan (LAM), a component of the Mycobacterium tuberculosis (MTB) cell wall, is detectable in the urine of MTB infected patients with active tuberculosis (TB). LAM-specific antibodies (Igs) have been developed by a variety of traditional and recombinant methods for potential use in a rapid diagnostic test (RDT). We evaluated the analytical performance of the TB LAM Igs to identify pairs that offer superior performance over existing urine LAM tests. We assessed 25 new and 4 existing Igs in a matrixed format using a multiplex electrochemiluminescence-based liquid immunoassay. A total of 841 paired Ig combinations were challenged with in vitro cultured LAM (cLAM) derived from MTB strains representing diverse phylogenetic lineages, alongside urinary LAM (uLAM) from the urine of adults with active pulmonary TB. Analytical sensitivity of down-selected Ig pairs was determined using MTB Aoyama-B cLAM, while diagnostic accuracy was determined using clinical samples. When testing cLAM, the reactivity of Ig pairs was similar across MTB lineages 1–4 but lineage 5:6 had significantly more reactivity among Ig pairs. Overall, 41 Ig pairs had a strong binding affinity to cLAM, as compared to the reference pair of S4-20/A194-01, and 28 Ig pairs therein exhibited a strong affinity for both cLAM and uLAM. Retrospective testing on clinical urine specimens demonstrated varying sensitivities (12–80%) and specificities (14–100%). The five top pairs had a similar analytical limit of detection to the reference pair but in four instances, the sensitivity and specificity with clinical uLAM samples was poor. Overall, epitopes presented by uLAM are different from cLAM, which may affect antibody performance when testing uLAM in patient samples. Several new Ig pairs had similar ranges of high sensitivity to cLAM but overall, there were no new candidate Ig pairs identified in this round of screening with increased performance with uLAM as compared to an existing optimal pair. |
format | Online Article Text |
id | pubmed-9524686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-95246862022-10-01 Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis Cantera, Jason L. Lillis, Lorraine M. Peck, Roger B. Moreau, Emmanuel Schouten, James A. Davis, Paul Drain, Paul K. Andama, Alfred Pinter, Abraham Kawasaki, Masanori Källenius, Gunilla Sundling, Christopher Dobos, Karen M. Flores, Danara Chatterjee, Delphi Murphy, Eileen Halas, Olivia R. Boyle, David S. PLoS One Research Article Lipoarabinomannan (LAM), a component of the Mycobacterium tuberculosis (MTB) cell wall, is detectable in the urine of MTB infected patients with active tuberculosis (TB). LAM-specific antibodies (Igs) have been developed by a variety of traditional and recombinant methods for potential use in a rapid diagnostic test (RDT). We evaluated the analytical performance of the TB LAM Igs to identify pairs that offer superior performance over existing urine LAM tests. We assessed 25 new and 4 existing Igs in a matrixed format using a multiplex electrochemiluminescence-based liquid immunoassay. A total of 841 paired Ig combinations were challenged with in vitro cultured LAM (cLAM) derived from MTB strains representing diverse phylogenetic lineages, alongside urinary LAM (uLAM) from the urine of adults with active pulmonary TB. Analytical sensitivity of down-selected Ig pairs was determined using MTB Aoyama-B cLAM, while diagnostic accuracy was determined using clinical samples. When testing cLAM, the reactivity of Ig pairs was similar across MTB lineages 1–4 but lineage 5:6 had significantly more reactivity among Ig pairs. Overall, 41 Ig pairs had a strong binding affinity to cLAM, as compared to the reference pair of S4-20/A194-01, and 28 Ig pairs therein exhibited a strong affinity for both cLAM and uLAM. Retrospective testing on clinical urine specimens demonstrated varying sensitivities (12–80%) and specificities (14–100%). The five top pairs had a similar analytical limit of detection to the reference pair but in four instances, the sensitivity and specificity with clinical uLAM samples was poor. Overall, epitopes presented by uLAM are different from cLAM, which may affect antibody performance when testing uLAM in patient samples. Several new Ig pairs had similar ranges of high sensitivity to cLAM but overall, there were no new candidate Ig pairs identified in this round of screening with increased performance with uLAM as compared to an existing optimal pair. Public Library of Science 2022-09-30 /pmc/articles/PMC9524686/ /pubmed/36178936 http://dx.doi.org/10.1371/journal.pone.0274415 Text en © 2022 Cantera et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Cantera, Jason L. Lillis, Lorraine M. Peck, Roger B. Moreau, Emmanuel Schouten, James A. Davis, Paul Drain, Paul K. Andama, Alfred Pinter, Abraham Kawasaki, Masanori Källenius, Gunilla Sundling, Christopher Dobos, Karen M. Flores, Danara Chatterjee, Delphi Murphy, Eileen Halas, Olivia R. Boyle, David S. Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis |
title | Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis |
title_full | Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis |
title_fullStr | Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis |
title_full_unstemmed | Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis |
title_short | Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis |
title_sort | performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for mycobacterium tuberculosis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524686/ https://www.ncbi.nlm.nih.gov/pubmed/36178936 http://dx.doi.org/10.1371/journal.pone.0274415 |
work_keys_str_mv | AT canterajasonl performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT lillislorrainem performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT peckrogerb performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT moreauemmanuel performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT schoutenjamesa performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT davispaul performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT drainpaulk performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT andamaalfred performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT pinterabraham performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT kawasakimasanori performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT kalleniusgunilla performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT sundlingchristopher performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT doboskarenm performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT floresdanara performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT chatterjeedelphi performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT murphyeileen performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT halasoliviar performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis AT boyledavids performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis |